Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$254 Mln
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
Debt to Equity
-0.63
ROE
0 %
ROCE
92.61 %
Div. Yield
0 %
Book Value
--
EPS
-0.51
CFO
$-170.16 Mln
EBITDA
$-226.31 Mln
Net Profit
$-376.05 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
| -29.07 | -11.09 | -18.28 | -34.42 | 6.51 | -7.31 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Aquestive Therapeutics (AQST)
| 75.43 | 123.92 | -76.81 | -27.29 | -8.08 | -7.62 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.26 | 11,509.07 | 27.16 | 8.05 | |
| 63.19 | 7,341.95 | 56.58 | 23.56 | |
| 58.36 | 11,313.41 | 389.73 | 0.76 | |
| 7.57 | 8,928.80 | -- | -3.24 |
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of... buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. Address: 30 Technology Drive, Warren, NJ, United States, 07059 Read more
CEO, President & Director
Mr. Daniel Barber
CEO, President & Director
Mr. Daniel Barber
Headquarters
Warren, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aquestive Therapeutics Inc (AQST) stood at $ 101 Mln as on 31-Dec-24
The share price of Aquestive Therapeutics Inc (AQST) is $2.53 (NASDAQ) as of 17-Apr-2025 12:40 EDT. Aquestive Therapeutics Inc (AQST) has given a return of 6.51% in the last 3 years.
Aquestive Therapeutics Inc (AQST) has a market capitalisation of $ 254 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Aquestive Therapeutics Inc (AQST) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aquestive Therapeutics Inc (AQST) and enter the required number of quantities and click on buy to purchase the shares of Aquestive Therapeutics Inc (AQST).
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. Address: 30 Technology Drive, Warren, NJ, United States, 07059
The CEO & director of Mr. Daniel Barber. is Aquestive Therapeutics Inc (AQST), and CFO & Sr. VP is Mr. Daniel Barber.
There is no promoter pledging in Aquestive Therapeutics Inc (AQST).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,140
|
|
|
1,139
|
|
|
930
|
|
|
770
|
| Aquestive Therapeutics Inc. (AQST) | Ratios |
|---|---|
|
Return on equity(%)
|
52.97
|
|
Operating margin(%)
|
-47.49
|
|
Net Margin(%)
|
-76.68
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aquestive Therapeutics Inc (AQST) was $0 Mln.
$0.03
(
